08.08.26 -- Outsourced Pharma Newsletter - Best Of July

Where CDMOs first flourish, and clinical trials pick up, biotech innovation follows. It has been the China model, and now the addition of biotechs and biotech investment from within and without has South Korea as the new attention-grabbing nation participating throughout our industry. Here's an in-depth analysis from Chief Editor Louis Garguilo.

From impurity control to technology transfer governance, these practical lessons will help sponsors navigate the realities of oligonucleotide manufacturing scale-up.

Chief Editor Louis Garguilo is concerned about how drug sponsors evaluate external partners. "Beware the selection of CDMOs for factors over fundamentals," he writes in his latest editorial. This injunction warns against getting entangled in a spreadsheet of details when choosing a CDMO. It’s a difficult task. We continue to add factors we deem as crucial to the selection process, and thus have arrived at the point where we actually talk ourselves out of opting for the best CDMO for our needs.

Pharmaceutical manufacturing facilities require active management and engineering expertise to balance costs, plan long-term infrastructure, and minimize production downtime.

Discover how PBPK models combined with in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development.

Gain insights into how standardized quality controls, robust analytics, and streamlined processes can improve efficiency, reliability, and scalability across the development lifecycle.